Researchers at FidoCure and Stanford University have published a peer-reviewed article in Nature Scientific Reports titled, "Real-world evidence couples genomic biomarkers with therapeutic outcomes fo...
Findings show precision medicine may rewrite fatal cancer outcomes
PALO ALTO, Calif.: Researchers at FidoCure and Stanford University have published a peer-reviewed article in Nature Scientific Reports titled, "Real-world evidence couples genomic biomarkers with therapeutic outcomes for canine hemangiosarcoma,” revealing how genomic profiling and targeted therapies can significantly improve patient outcomes for the largest unmet need for dogs: cancer.
The study analyzed data from 508 pet dog patients enrolled in the FidoCure® Precision Medicine Platform with splenic hemangiosarcoma (HSA) and revealed survival benefits to patients treated with precision therapeutics. These findings highlight the value of using genomic profiling to personalize targeted therapy selection for canine cancer, as well as for genetically analogous human cancers, like human angiosarcoma.
"This study demonstrates the power of precision medicine in oncology, which we have known for decades is key in human patients, and now adds the dimension of cross-species comparisons," said George Demetri, MD, professor of medicine at Dana-Farber Cancer Institute and Harvard Medical School. "We're seeing tangible benefits of tailoring treatments to a dog's specific tumor profile, which could revolutionize how we approach cancer care for our canine companions. This also opens up the future dimensions of how we might learn lessons from our companion animals that could inform our research and therapies for humans with some of the most relentless cancers that afflict both humans and dogs. A big opening is clear for new research and therapy initiatives."
Hemangiosarcoma is the biggest unmet need for dogs, with patients that receive the fatal diagnosis often euthanized shortly after. The study is the first to reveal the relationships between specific genetic mutations, the use of targeted therapies, and survival outcomes for this canine cancer. The findings mark a significant advancement for precision medicine in veterinary oncology and further support the role of genomics in guiding more effective, individualized cancer care to transform one of the most aggressive cancers in dogs.
Key findings include:
"This study represents a major step forward in clinical care for canine hemangiosarcoma," said Christina Lopes, founder and CEO of FidoCure. "By leveraging AI, advanced genomic profiling, and targeted therapies, we are transforming a deadly cancer in dogs into a second chance at life—and gaining valuable insights for rare human cancers too.”
This is FidoCure’s 4th peer-reviewed paper in two years and their second major study on hemangiosarcoma. The first HSA study, published in Veterinary and Comparative Oncology, was recognized as one of the Top 10 Most-Cited Articles of 2023 for the leading veterinary publication. Together, these studies provide some of the most comprehensive real-world data available for this cancer type, and they are helping to redefine what’s possible in oncology—for both sides of the leash.
ABOUT FIDOCURE
FidoCure is an AI-driven precision oncology company transforming cancer in dogs through novel targeted therapies. FidoCure has created the world’s largest canine cancer dataset, with over 2 billion data points collected from patients treated in its network of 1,350 veterinary clinics worldwide. Learn more at www.fidocure.com.
Fonte: Business Wire
Alaa Abdul Nabi, Vice President, Sales International at RSA presents the innovations the vendor brings to Cybertech as part of a passwordless vision for…
G11 Media's SecurityOpenLab magazine rewards excellence in cybersecurity: the best vendors based on user votes
Always keeping an European perspective, Austria has developed a thriving AI ecosystem that now can attract talents and companies from other countries
Successfully completing a Proof of Concept implementation in Athens, the two Italian companies prove that QKD can be easily implemented also in pre-existing…
Today, Securonix, a five-time Leader in the Gartner® Magic Quadrant™ for Security Information and Event Management (SIEM), announced the acquisition of…
PubNub, the leader in real-time interactive apps, unveiled the next evolution of its platform. It introduces AI-native development, real-time decision…
Anjuna, a leader in Confidential Computing and AI Data Fusion Clean Rooms, today announced the addition of a new top five global bank to its growing roster…
Work AI leader Glean today announced it raised $150 million in Series F financing, bringing its valuation to $7.2 billion. The round was led by Wellington…